36 results about "Therapeutic drug monitoring" patented technology

The present invention includes systems and methods for monitoring therapeutic drug concentration in blood by detecting markers, such as odors, upon exhalation by a patient after the drug is taken, wherein such markers result either directly from the drug itself or from an additive combined with the drug. In the case of olfactory markers, the invention preferably utilizes electronic sensor technology, such as the commercial devices referred to as “artificial” or “electronic” noses or tongues, to non-invasively monitor drug levels in blood. The invention further includes a reporting system capable of tracking drug concentrations in blood (remote or proximate locations) and providing the necessary alerts with regarding to ineffective or toxic drug dosages in a patient.

This invention relates to the production of polyclonal and monoclonal antibodies to specific sites of rapamycin (Sirolimus). The reactivity of these poly and monoclonal antibodies make them particularly useful for immunoassays for therapeutic drug monitoring (TDM). These immunoassays or TDM kits may include polyclonal or monoclonal antibodies to specific sites of rapamycin. These kits may also include various combinations of polyclonal antibodies, polyclonal and monoclonal antibodies or a panel of monoclonal antibodies. Rapamycin conjugate immunogens are prepared for the immunization of a host animal to produce antibodies directed against specific regions of the rapamycin molecule. By determining the specific binding region of particular antibody, immunoassays which are capable of distinguishing between the parent molecule, active metabolites, inactive metabolites and other structurally similar immunosuppressant compounds are developed. The use of divinyl sulfone (DVS) as the linker arm molecule for forming rapamycin-protein conjugate immunogens is described. DVS-linked rapamycin-protein conjugates were found to elicit antibodies with greater specificity to the rapamycin molecule than succinate linked conjugates.

A method of using a diffusion-based, continuous-monitoring system to monitor the effectiveness of delivering a drug includes creating and maintaining a diffusion channel in an area of skin. The levels of the drug, metabolite, or affected substance of the drug are continuously monitored in the area of the skin for a desired duration via a diffusion-based, continuous-monitoring device. The levels of the drug, the metabolite, or affected substance is analyzed to determine the effectiveness of delivering the therapeutic drug.

The invention belongs to the field of drug detection, and particularly relates to a method and a kit for detecting five psychotropic drugs and main metabolites thereof in blood. The five psychotropicdrugs and the main metabolites thereof comprise: olanzapine and demethyl olanzapine, risperidone and 9-hydroxy risperidone, aripiprazole and dehydrogenated aripiprazole, Escitalopram and demethyl citalopram, sertraline and N-demethyl sertraline. Accoridng to the method provided by the invention, a pair of quantitative ion pairs is respectively selected for each detection substance, a relative retention time thereof is used as a qualitative basis, and a standard curve is made by using a standard product for quantification; furthermore, the accuracy and effectiveness of the method are evaluatedfrom quality control of three low, middle and high levels, thereby avoiding distortion of the detection result; and meanwhile, an internal standard working solution is applied to correction, so that matrix effects can be avoided, and accurate quantification is realized. The method provided by the invention has the advantages of simple and rapid operation, high flux and low cost, and can be appliedto the therapeutic drug monitoring of the psychotropic drugs in the clinical work of the psychiatry department.

Methods for the simultaneous or sequential analysis and quantification of a plurality of antiretroviral analytes in a complex biological matrix by mass spectrometry are disclosed. The methods require minimal sample size, minimal preparation time and allow for rapid through-put. The system is particularly useful in therapeutic drug monitoring.

Methods, devices, and compositions for assaying therapeutic agents. In one aspect, methods, devices, and compositions for assaying paclitaxel to provide therapeutic drug monitoring guided therapy of paclitaxel.

Disclosed are methods and kits for pharmacokinetic profiling employing point-of-care or point of service self-sampling and allowing for dosage adjustments based on the pharmacokinetic profiles.

The invention relates to the field of medical detection and in particular to a blood donepezil therapeutic drug monitoring kit developed based on multi-dimensional online solid-phase extraction liquidchromatography analytical technology, more specifically to a method for accurately and quantitatively detecting donepezil drug concentration in blood by online solid-phase extraction and multi-dimensional liquid chromatography analytical technology. The kit includes a calibration reagent, a quality control reagent, a processing liquid, an extract liquid, a washing liquid, and an eluent. The therapeutic drug monitoring kit of the invention only needs to centrifuge a blood sample, achieves low repeated detection variability, high accuracy and stability, and low detection cost, has various methodological indicators that satisfy the requirement for monitoring the blood donepezil therapeutic drugs, and is easy to generalize.

The invention relates to therapeutic drug monitoring (TDM) by mass spectrometry, particularly to the monitoring of immunosuppressant levels in blood of patients with transplanted organs. A liquid phase extraction procedure reproducibly extracts the therapeutic drug molecules from whole blood and mass spectrometric analysis on MALDI instruments, with a matrix substance for highest sensitivity and special sample deposition procedure for a reproducible ionization of the therapeutic drug molecules. Suitable internal standard substances added to the blood in exact amounts ensure a correct absolute quantification. The method is particularly suitable for immunosuppressants belonging to the class of macrocyclic lactones (sirolimus, tacrolimus, everolimus) and cyclic polypeptides (cyclosporin A), and even works as a multiplex method for all four immunosuppressants simultaneously.

Methods for therapeutic drug monitoring are provided. A plurality of particles, each of which is coated with a capture agent capable of binding a therapeutic drug of choice is combined with the sample to form a plurality of therapeutic drug-particle complexes. The system also includes a transport arrangement for transporting the sample and/or particles to the sensor surface, and optionally a magnetic field inducing structure constructed and arranged to establish a magnetic field at and adjacent to the sensor surface. The resonant sensor produces a signal corresponding to an amount of therapeutic drug-particle complexes that are bound to the sensor surface.

The invention relates to the field of medical detection and in particular to a blood amiodarone therapeutic drug monitoring kit developed based on multi-dimensional online solid-phase extraction liquid chromatography analytical technology, more specifically to a method for accurately and quantitatively detecting amiodarone drug concentration in blood by online solid-phase extraction and multi-dimensional liquid chromatography analytical technology. The kit includes a calibration reagent, a quality control reagent, a processing liquid, an extract liquid, a washing liquid, and an eluent. The therapeutic drug monitoring kit of the invention only needs to centrifuge a blood sample, achieves low repeated detection variability, high accuracy and stability, and low detection cost, has various methodological indicators that satisfy the requirement for monitoring the blood amiodarone therapeutic drugs, and is easy to generalize.

The invention relates to the field of medical detection and in particular to a blood linezolid therapeutic drug monitoring kit developed based on multi-dimensional online solid-phase extraction liquidchromatography analytical technology, more specifically to a method for accurately and quantitatively detecting linezolid drug concentration in blood by online solid-phase extraction and multi-dimensional liquid chromatography analytical technology. The kit includes a calibration reagent, a quality control reagent, a processing liquid, an extract liquid, a washing liquid, and an eluent. The therapeutic drug monitoring kit of the invention only needs to centrifuge a blood sample, achieves low repeated detection variability, high accuracy and stability, and low detection cost, has various methodological indicators that satisfy the requirement for monitoring the blood linezolid therapeutic drugs, and is easy to generalize.

The invention relates to the field of medicine detection, in particular to a kit, for therapeutic drug monitoring of fluconazole in blood, developed on the basis of a multi-dimensional online solid phase extraction and liquid chromatography analysis technology, and more specifically discloses a method for carrying out accurate quantitative detection on the concentration of a fluconazole drug in blood by adopting an online solid phase extraction and multi-dimensional liquid chromatography analysis technology. The kit comprises a calibrator reagent, a quality control material reagent, treating fluid, extracting fluid, cleaning fluid and an eluent. According to the kit for therapeutic drug monitoring disclosed by the invention, only centrifugal treatment is needed for a blood sample, so thatthe repeated detection variability is small, the accuracy and the stability are high, the detection cost is low, and various methodology indicators all can meet the requirements of therapeutic drug monitoring of the fluconazole in the blood, and the kit is easy to promote.

The invention relates to the field of medical detection and in particular to a blood lamotrigine therapeutic drug monitoring kit developed based on multi-dimensional online solid-phase extraction liquid chromatography analytical technology, more specifically to a method for accurately and quantitatively detecting lamotrigine drug concentration in blood by online solid-phase extraction and multi-dimensional liquid chromatography analytical technology. The kit includes a calibration reagent, a quality control reagent, a processing liquid, an extract liquid, a washing liquid, and an eluent. The therapeutic drug monitoring kit of the invention only needs to centrifuge a blood sample, achieves low repeated detection variability, high accuracy and stability, and low detection cost, has various methodological indicators that satisfy the requirement for monitoring the blood lamotrigine therapeutic drugs, and is easy to generalize.

The invention discloses an HIS based intelligent therapeutic drug monitoring whole process management system and a method thereof. The therapeutic drug monitoring whole process management system comprises a management control system, an HIS system, a TDM knowledge database, a prompt information base and a nursing workstation, wherein the management control system comprises a control module as well as an extraction module, a query module and a storage writing module connected with the control module, the output end of the HIS system is connected with the input end of the extraction module, the query module is connected with the TDM knowledge database and the prompt information base, the storage writing module is connected with the TDM knowledge database and the prompt information base, and the nursing workstation is connected with the control module. The system can effectively avoid the repeated detection of drug related genes, ensure the qualified rate of plasma concentration specimens, improve the working efficiency of the staff, and reduce the waste of medical resources fundamentally.

The invention provides novel haptens and immunogens for the preparation of novel monoclonal antibodies, which detect the synthetic opioid meperidine and its active metabolite normeperidine. These antibodies enable methods and kits, which are useful in an immunoassay for therapeutic drug monitoring (TDM) and in extending the window of detection for cases of abuse and drug-facilitated sexual assault (DFSA).

Disclosed herein are methods and compositions for antimicrobial quantification and functional measurement. In one aspect, a method for quantifying antimicrobial comprises: obtaining a biological sample from a patient receiving an antimicrobial; incubating the biological sample with a reference microbial strain and a fluorophore for detecting cell lesion; measuring a first signal of fluorescent intensity in the incubated biological sample using flow cytometry; and comparing the first signal to a calibrating curve previously generated for the antimicrobial, thereby quantifying the antimicrobial present in the biological sample.

The invention provides methods for treating humans in need of combined immunosuppressant and biological response modifier therapy.